The table below shows Sarepta Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$202.68M
-$583.44M
-$242.08M
-$209.40M
-$101.17M
-$180.37M
Capital expenditure
$2.08M
$43.65M
$32.44M
$9.48M
$5.55M
$21.15M
Investing cash flow
-$134.39M
-$291.18M
$218.80M
$12.49M
-$785.81M
$156.67M
Dividends paid
-
-
-
SRPT operating cash flow (10-K history)
Sarepta Therapeutics, Inc. reported operating cash flow of -$205.48M for fiscal year 2025. That is up 0.1% from -$205.79M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$245.82M (FY 2016) to -$205.48M. Figures come from the company's audited annual reports as filed with the SEC.
